Filter Results
:
(80)
Show Results For
-
All HBS Web
(184)
- People (1)
- News (53)
- Research (80)
- Events (3)
- Multimedia (9)
- Faculty Publications (48)
Show Results For
-
All HBS Web
(184)
- People (1)
- News (53)
- Research (80)
- Events (3)
- Multimedia (9)
- Faculty Publications (48)
Sort by
- February 2021
- Case
Digital Manufacturing at Amgen
By: Shane Greenstein, Kyle R. Myers and Sarah Mehta
This case discusses efforts made by biotechnology (biotech) company Amgen to introduce digital technologies into its manufacturing processes. Doing so is complicated by the fact that the process for manufacturing biologics—or therapeutics made from living cells—is...
View Details
Keywords:
Digital Technologies;
Change;
Change Management;
Decision Making;
Cost vs Benefits;
Decisions;
Information;
Analytics and Data Science;
Innovation and Invention;
Innovation and Management;
Innovation Leadership;
Innovation Strategy;
Technological Innovation;
Jobs and Positions;
Knowledge;
Leadership;
Organizational Culture;
Science;
Strategy;
Information Technology;
Technology Adoption;
Biotechnology Industry;
Pharmaceutical Industry;
United States;
California;
Puerto Rico;
Rhode Island
Greenstein, Shane, Kyle R. Myers, and Sarah Mehta. "Digital Manufacturing at Amgen." Harvard Business School Case 621-008, February 2021.
- Article
Comparative Costs of Advanced Proton and Photon Radiation Therapies: Lessons from Time-driven Activity-based Costing in Head and Neck Cancer
By: Nikhil G. Thaker, Steven J. Frank and Thomas W. Feeley
Time-driven activity-based costing (TDABC) is an innovative costing tool in healthcare that can be used to directly compare the true cost of competing technologies over the full care cycle. Rather than only comparing therapeutic effectiveness over a limited number of...
View Details
Keywords:
Head And Neck Cancer;
IMRT;
Proton Therapy;
Time-Driven ABC;
Information Technology;
Activity Based Costing and Management;
Medical Specialties
Thaker, Nikhil G., Steven J. Frank, and Thomas W. Feeley. "Comparative Costs of Advanced Proton and Photon Radiation Therapies: Lessons from Time-driven Activity-based Costing in Head and Neck Cancer." Journal of Comparative Effectiveness Research 4, no. 4 (2015): 297–301.
- May 2017
- Other Article
Stepwise Distributed Open Innovation Contests for Software Development: Acceleration of Genome-Wide Association Analysis
By: Andrew Hill, Po-Ru Loh, Ragu B. Bharadwaj, Pascal Pons, Jingbo Shang, Eva C. Guinan, Karim R. Lakhani, Iain Kilty and Scott Jelinsky
BACKGROUND:
The association of differing genotypes with disease-related phenotypic traits offers great potential to both help identify new therapeutic targets and support stratification of patients who would gain the greatest benefit from specific drug classes....
View Details
Keywords:
Crowdsourcing;
Genome-wide Association Study;
Logistic Regression;
Open Innovation;
PLINK;
Collaborative Innovation and Invention
Hill, Andrew, Po-Ru Loh, Ragu B. Bharadwaj, Pascal Pons, Jingbo Shang, Eva C. Guinan, Karim R. Lakhani, Iain Kilty, and Scott Jelinsky. "Stepwise Distributed Open Innovation Contests for Software Development: Acceleration of Genome-Wide Association Analysis." GigaScience 6, no. 5 (May 2017).
- January 2016 (Revised January 2019)
- Case
The Allergan Board Under Fire (A)
By: Lynn S. Paine, Suraj Srinivasan, John C. Coates and David Lane
In 2014, the Allergan Inc. board of directors received a surprise takeover offer from Valeant Pharmaceuticals in alliance with hedge fund activist Bill Ackman's Pershing Square Capital Management. In the unprecedented arrangement between an acquirer and a hedge fund...
View Details
Keywords:
Allergan, Inc.;
Valeant;
Ackman;
Pershing Square;
Tender Offer;
Activist Investors;
Business Models;
R&D;
Board Of Directors;
Securities Litigation;
Acquisition Strategy;
Takeover Defenses;
Hedge Funds;
Shareholder Rights;
Proxy Contest;
Shareholder Special Meetings;
Legal Issues In Contested Takeovers;
Governing and Advisory Boards;
Mergers and Acquisitions;
Corporate Governance;
Management Teams;
Business and Shareholder Relations;
Pharmaceutical Industry
Paine, Lynn S., Suraj Srinivasan, John C. Coates, and David Lane. "The Allergan Board Under Fire (A)." Harvard Business School Case 316-010, January 2016. (Revised January 2019.)
- January 2016 (Revised January 2019)
- Supplement
The Allergan Board Under Fire (B)
By: Lynn S. Paine, Suraj Srinivasan, John C. Coates and David Lane
In 2014, the Allergan Inc. board of directors received a surprise takeover offer from Valeant Pharmaceuticals in alliance with hedge fund activist Bill Ackman's Pershing Square Capital Management. In the unprecedented arrangement between an acquirer and a hedge fund...
View Details
Keywords:
Allergan, Inc.;
Valeant;
Ackman;
Pershing Square;
Tender Offer;
Activist Investors;
Business Models;
R&D;
Board Of Directors;
Securities Litigation;
Acquisition Strategy;
Takeover Defenses;
Hedge Funds;
Shareholder Rights;
Proxy Contest;
Shareholder Special Meetings;
Legal Issues In Contested Takeovers;
Corporate Governance;
Investment Activism;
Business and Stakeholder Relations;
Business Model;
Business and Shareholder Relations;
Valuation;
Pharmaceutical Industry
Paine, Lynn S., Suraj Srinivasan, John C. Coates, and David Lane. "The Allergan Board Under Fire (B)." Harvard Business School Supplement 316-029, January 2016. (Revised January 2019.)
- January 2001 (Revised July 2003)
- Case
Pharmacyclics: Financing Research & Development
By: Malcolm P. Baker, Richard S. Ruback and Aldo Sesia
Pharmacyclics (NASDAQ: PCYC), a pharmaceutical company that manufactures products that will improve existing therapeutic treatments for cancer, arteriosclerosis, and retinal disease, was considering a $60 million private placement in February 2000. The company had more...
View Details
Keywords:
Valuation;
Cash Flow;
Financing and Loans;
Business Startups;
Financial Strategy;
Medical Devices and Supplies Industry;
Pharmaceutical Industry;
Health Industry
Baker, Malcolm P., Richard S. Ruback, and Aldo Sesia. "Pharmacyclics: Financing Research & Development." Harvard Business School Case 201-056, January 2001. (Revised July 2003.)
- Article
Sustainability, Business, and Health
By: George Serafeim, Amanda M. Rischbieth and Howard K. Koh
The coronavirus disease 2019 (COVID-19) pandemic has demonstrated that response demands involvement from every sector of society. As a major example, some businesses have stepped up in ways previously unimaginable. Garment companies have repurposed production to face...
View Details
Keywords:
COVID;
COVID-19;
Sustainability;
Health And Wellness;
Corporate Social Responsibility;
Health Pandemics;
Health;
Corporate Social Responsibility and Impact;
Corporate Accountability;
Health Care and Treatment
Serafeim, George, Amanda M. Rischbieth, and Howard K. Koh. "Sustainability, Business, and Health." JAMA, the Journal of the American Medical Association 324, no. 2 (July 14, 2020): 147–148.
- September 2020
- Case
Minerva 2010: Turbulent Times
By: John R. Wells and Benjamin Weinstock
In 2010, amid a flurry of new discoveries, Cynthia Bamdad, founder and CEO of Minerva Biotechnologies Corporation (Minerva), raised $6.6 million to test her new cancer drugs in mice. It had been more than 6 years since she had announced that she and her small team at...
View Details
Wells, John R., and Benjamin Weinstock. "Minerva 2010: Turbulent Times." Harvard Business School Case 721-390, September 2020.
- 12 Jul 2016
- First Look
July 12, 2016
spending. Whereas traditional (small-molecule) drugs have historically faced price competition from generic drugs after patent expiration, biosimilars—biologic drugs that have been shown to be therapeutically equivalent to an already...
View Details
Keywords:
Sean Silverthorne
- May 2024
- Article
Tepid Uptake of Digital Health Technologies in Clinical Trials by Pharmaceutical and Medical Device Firms
By: Caroline Marra and Ariel D. Stern
Digital health technologies (DHTs) can enable more patient-centric therapeutic development by generating evidence that captures how patients feel and function, enabling decentralized trial designs that increase participant inclusivity and convenience, and collecting...
View Details
Keywords:
Health Care and Treatment;
Technological Innovation;
Product Development;
Health Testing and Trials;
Governing Rules, Regulations, and Reforms
Marra, Caroline, and Ariel D. Stern. "Tepid Uptake of Digital Health Technologies in Clinical Trials by Pharmaceutical and Medical Device Firms." Clinical Pharmacology & Therapeutics 115, no. 5 (May 2024): 988–992.
- 11 Oct 2011
- Working Paper Summaries
US Healthcare Reform and the Pharmaceutical Industry
- 12 Jun 2018
- Research & Ideas
In a Landscape of 'Me Too' Drug Development, What Spurs Radical Innovation?
drug development—therapies that are chemically similar to established drugs—rather than on riskier, novel drugs. Critics say this tendency helps explain why therapeutic breakthroughs are increasingly less frequent. “When firms are making...
View Details
- 03 Dec 2001
- Research & Ideas
Healthcare Conference Looks At Ailing Industry
medicine is that most therapeutics were directed at symptoms, not causes.—Eric S. Lander With that in mind, about 200 HBS alumni working in the healthcare field converged in mid-November at the Charles Hotel in Cambridge to learn from...
View Details
- 18 Nov 2014
- First Look
First Look: November 18
the continuing battle affect management, talent, and the company's financial performance? Purchase this case: https://hbr.org/product/Turkcell/an/715009-PDF-ENG Harvard Business School Case 615-024 Pfizer's Centers for Therapeutic...
View Details
Keywords:
Sean Silverthorne
- 13 May 2002
- Book
Bringing the Master Passions to Work
stand ever in need of repression, suppression, or the therapeutic influence of reason. What we cannot explain must often remain hidden. Hence, the student of passions should take the stance of a detective or a spy, seeking to expose the...
View Details
Keywords:
by Mihnea C. Moldoveanu & Nitin Nohria
- 26 Nov 2013
- First Look
First Look: November 26
Beshears, John, James J. Choi, David Laibson, Brigitte C. Madrian, and Gwendolyn Reynolds Abstract—Objectives: To assess whether the addition of a peer testimonial to an informational mailing increases conversion rates from brand name prescription medications to...
View Details
Keywords:
Sean Silverthorne
- 24 Jan 2017
- First Look
First Look at New Research: January 24, 2017
Business School Case 617-029 Anthony Starks at InSiL Therapeutics (A) When Bruce Wayne hired Anthony Starks, he thought he had hit a home run by getting the most brilliant and passionate scientist-leader in the field to be his CSO. But a...
View Details
Keywords:
Sean Silverthorne
- 23 Mar 2021
- Book
Succeeding in the New Work-from-Anywhere World
than fifty years, self-disclosure has been widely studied across a variety of interpersonal contexts, including friendships, romances, and therapeutic relations. The way to enhance trust between people is for all parties to self-disclose,...
View Details
Keywords:
by Michael Blanding
- 07 Aug 2000
- Research & Ideas
The Business of Biotech
"But in order to determine that genetic information has a therapeutic use, we have to make a substantial investment—$350 to $500 million—in doing the clinical trial work. From a business standpoint, we need to protect our...
View Details
- 18 Dec 2018
- First Look
New Research and Ideas, December 18, 2018
from other firms, rather than developing new projects internally. Examining the channels behind this increase in R&D in-licensing, we explore heterogeneity in treatment effects and competitor spillovers. We find that competitors move resources away from affected...
View Details
Keywords:
Dina Gerdeman